The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study
| Autor: | Sergio Giralt, Jorge Vela-Ojeda, Amelia Morales-Toquero, Guillermo J. Ruiz-Argüelles, Carmino DeSouza, E. Miranda, César Homero Gutiérrez-Aguirre, Carlos Manzano, David Gómez-Almaguer, Abraham Sumoza, Amado Karduss, M. A. García-Ruiz-Esparza |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Transplantation Conditioning Adolescent Immunology Graft vs Host Disease Antigens CD34 Antineoplastic Agents Philadelphia chromosome Biochemistry Piperazines Sepsis Myelogenous Leukemia Myelogenous Chronic BCR-ABL Positive Internal medicine Humans Medicine In patient Prospective Studies Child Aged Transplantation Hematology business.industry Imatinib Reduced intensity Cell Biology Middle Aged medicine.disease Surgery Leukemia Pyrimidines Treatment Outcome Graft-versus-host disease Multicenter study Benzamides Blood Component Removal Imatinib Mesylate Female Stem cell business Stem Cell Transplantation Early referral Chronic myelogenous leukemia medicine.drug |
| Zdroj: | Blood. 106:4838-4838 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v106.11.4838.4838 |
| Popis: | Using a reduced intensity stem cell transplantation (RIST) schedule, 24 patients with Ph1 (+) chronic myelogenous leukemia (CML) in first chronic phase were prospectively allografted in four Latin American countries: Mexico, Brasil, Colombia and Venezuela, using HLA-identical siblings as donors. Median age of the patients was 41 years (range 10 to 71); there were 8 females. Patients received a median of 4.4 x 106/ Kg CD34 cells. Median time to achieve above 0.5 x 109/L granulocytes was 12 days, range 0–41, whereas median time to achieve above 20 x 109/L platelets was also 12 days, range 0–45. Twenty two patients are alive 81 to 830 (median 497) days after the RIST. The 830-day probability of survival is 92%, whereas median survival has not been reached, being above 830 days. Eleven patients (46%) developed acute graft versus-host disease (GVHD), whereas 7 of 23 (30%) developed chronic GVHD. Two patients died 43 and 210 days after the RIST, one as a result of sepsis and the other one of chronic GVHD. The 100-day mortality was 4.4 %, whereas the transplant-related mortality was 8%. RIST for patients with CML in chronic phase seems as an adequate therapeutic option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|